The appointment is a positive scientific validation but does not change the near-term financial trajectory. Watch for initiation of clinical trials for NCEL-101 and any collaboration updates with Eledon Pharmaceuticals.
Price Chart
Executive Summary
NewcelX announced the appointment of Dr. Camillo Ricordi, a world-renowned diabetes researcher, to its Scientific Advisory Board, following a successful FDA Type B Pre-IND meeting for its lead T1D program NCEL-101. The appointment adds credibility but does not materially alter the company's near-term financial or regulatory outlook.
Key Facts
- Dr. Camillo Ricordi appointed to Scientific Advisory Board; he is a leading expert in islet transplantation and diabetes cure research.
- Appointment follows recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials.
- Dr. Ricordi will support NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals.
Financial Impact
Not specified
Risk Factors
- Clinical-stage company with substantial doubt about going concern (as noted in forward-looking statements).
- No new funding or revenue disclosed; continued reliance on capital markets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-076199 |
| Document: ea0297276-6k_newcelx.htm | 0001213900-26-076199 |
| Document: 0001213900-26-076199-index-headers.html | 0001213900-26-076199 |
| Document: 0001213900-26-076199-index.html | 0001213900-26-076199 |
| Document: 0001213900-26-076199.txt | 0001213900-26-076199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | EFFECT | $2.86 $3.08 | ▼ −7.52% | ▼ −8.19% | $2.55 (+10.84%) |
Sep 18, 2026 5w ago | 6-K | $2.97 $2.92 | ▲ +1.68% | ▲ +0.66% | $2.55 (+14.14%) |
Aug 27, 2026 8w ago | EFFECT | $3.42 $3.35 | ▲ +2.05% | ▲ +1.28% | $2.55 (+25.44%) |
Jul 31, 2026 12w ago | 6-K | $3.49 $3.31 | ▼ −5.16% | ▼ −8.67% | $2.55 (−26.93%) |
Jul 15, 2026 14w ago | 6-K | $3.93 $3.65 | ▼ −7.12% | ▼ −6.14% | $2.55 (−35.11%) |
Jul 8, 2026 15w ago | 6-K | $4.23 $3.98 | ▼ −5.91% | ▼ −6.77% | $2.55 (−39.72%) |
Jul 1, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 30, 2026 16w ago | 6-K | $3.85 $4.01 | ▲ +4.16% | ▲ +3.89% | $2.55 (−33.77%) |
Jun 18, 2026 18w ago | EFFECT | $3.31 $3.55 | ▼ −7.25% | ▼ −8.92% | $2.55 (+22.96%) |
Jun 5, 2026 20w ago | 6-K | $3.24 $3.20 | ▼ −1.23% | ▼ −3.35% | $2.55 (−21.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers